摘要
目的探讨新型冠状病毒肺炎(COVID-19)患者尿蛋白与病程的关系。方法收集268例COVID-19患者(轻/普通型246例、重/危重型22例)入院3 d内以及其中155例出院随访患者的新鲜尿液样本,采用干化学法行尿常规检测。以最终排除严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染的疑似患者125例为对照组。结果COVID-19轻/普通型组、重/危重型组入院时的尿蛋白阳性率均明显高于对照组(P<0.05),重/危重型组入院时的尿蛋白阳性率明显高于轻/普通型组(P<0.0001),出院随访时2个组之间尿蛋白阳性率差异无统计学意义(P>0.05)。按年龄分组,20~39岁组在入院时有23.53%(20/85)的患者尿蛋白呈阳性,出院随访时尿蛋白检测均为阴性;40~59岁组在入院时有38.20%(34/89)的患者尿蛋白呈阳性,出院随访时仍有5.26%的患者尿蛋白呈阳性。重/危重型组肌酐和尿素氮均高于轻/普通型组(P<0.0001)。结论尿蛋白对COVID-19患者病程进展有一定的指示作用。
Objective To investigate the correlation between urinary protein and disease progression in patients with corona virus disease 2019(COVID-19).Methods The fresh urine samples from 268 COVID-19 patients(246 cases of light/common type and 22 cases of severe/critical type)within 3 d of admission and 155 discharged patients were collected.Dry chemical analysis was used for routine urine test.Totally,125 suspected patients without severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection were enrolled as control group.Results The positive rates of urinary protein in severe/critical type group and light/common type group were higher than that in control group at admission(P<0.05).The positive rate of urinary protein in severe/critical type group was higher than that in light/common type group(P<0.0001),and there was no statistical significance for the positive rate between the 2 groups at dismission(P>0.05).There were 23.53%(20/85)patients in 20-39 years old group with positive urinary protein at admission and negative at dismission.There were 38.20%(34/89)patients in 40-59 years old group with positive urinary protein at admission and 5.26%patients with still positive urinary protein at dismission.Creatinine and urea nitrogen in severe/critical type group were higher than those in light/common type group(P<0.0001).Conclusions Urinary protein has an indicative effect on the progress of COVID-19.
作者
张腾飞
戚伟强
凌云
宰淑蓓
王棪
樊剑
张蓓
朱召芹
ZHANG Tengfei;QI Weiqiang;LING Yun;ZAI Shubei;WANG Yan;FAN Jian;ZHANG Bei;ZHU Zhaoqin(Shanghai Public Health Clinical Center,Shanghai 201508,China)
出处
《检验医学》
CAS
2020年第9期872-874,共3页
Laboratory Medicine
基金
国家“十三五”科技部重大专项项目(2018ZX10714002-001-005)
上海市科学技术委员会应急攻关项目(20411950502)
上海市公共卫生临床中心院内专项课题(2020YJKY01)。
